Sugi Predict

Sugi Predict / Compounds / SCHEMBL934710

SCHEMBL934710

SCHEMBL934710

FC(F)(F)Oc1cc(CBr)ccc1Cl

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ EPHX1 P07099 1/20 0.44
▸ KDM4A O75164 2/20 0.42
▸ KDM5A P29375 2/20 0.42
▸ NOTUM Q6P988 2/20 0.42
▸ KCNN4 O15554 1/20 0.40
▸ CYP4F2 P78329 1/20 0.40
▸ CYP4A11 Q02928 1/20 0.40
▸ PDE3A Q14432 1/20 0.38
▸ PGK1 P00558 1/20 0.38
▸ IDO1 P14902 2/20 0.37
▸ TRPV1 Q8NER1 1/20 0.35
▸ GRIN2B Q13224 1/20 0.35
▸ TSHR P16473 1/20 0.34
▸ RORC P51449 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27814902 0.86 EPHX1 (0.43) EPHX1KDM4AKDM5ANOTUMKCNN4
SCHEMBL101152 0.86 MEN1 (0.41) PGK1
SCHEMBL9824390 0.84 EPHX1 (0.45) EPHX1KDM4AKDM5ANOTUMKCNN4
SCHEMBL2239066 0.83 RXRA (0.37) TSHR
SCHEMBL3754799 0.82 EPHX1 (0.44) EPHX1KDM4AKDM5ANOTUMKCNN4
SCHEMBL2240142 0.82 NOTUM (0.51) EPHX1KDM4AKDM5ANOTUMKCNN4
SCHEMBL30176060 0.82 CSNK2A1 (0.47) EPHX1KDM4AKDM5ANOTUMKCNN4
SCHEMBL8185415 0.82 EPHX1 (0.44) EPHX1KDM4AKDM5ANOTUMKCNN4
SCHEMBL4374816 0.82 CSNK2A1 (0.47) EPHX1KDM4AKDM5ANOTUMKCNN4
SCHEMBL4444828 0.80 KCNN4 (0.41) KCNN4CYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4536643-A1 BENZOPYRIMIDIN-4(3H)-ONES AS PI3K INHIBITORS OnKure, Inc. (US) 2025-04-16 — — EP disclosed
CN-119744260-A Benzopyrimidin-4 (3H) -ones as PI3K inhibitors 恩库勒公司 2025-04-01 — — CN disclosed
WO-2024081345-A1 BENZOPYRIMIDIN-4(3H)-ONES AS PI3K INHIBITORS ONKURE, INC. (US) 2024-04-18 — — WO disclosed
WO-2024081345-A1 BENZOPYRIMIDIN-4(3H)-ONES AS PI3K INHIBITORS ONKURE, INC. (US) 2024-04-18 — — WO disclosed
WO-2023239710-A1 BENZOPYRIMIDIN-4(3H)-ONES AS PI3K INHIBITORS ONKURE, INC. (US) 2023-12-14 — — WO disclosed
US-20230002437-A1 ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF ANTENGENE THERAPEUTICS LIMITED (CN) 2023-01-05 — — US disclosed
US-11034715-B2 Ectonucleotidase inhibitors and methods of use thereof CALITHERA BIOSCIENCES, INC. (US) 2021-06-15 — — US disclosed
US-20200223882-A1 Ectonucleotidase Inhibitors and Methods of Use Thereof ANTENGENE THERAPEUTICS LIMITED (CN) 2020-07-16 — — US disclosed
US-10570167-B2 Ectonucleotidase inhibitors and methods of use thereof CALITHERA BIOSCIENCES, INC. (US) 2020-02-25 — — US disclosed
CN-106414429-B Pyrazole compounds and their use as T-type calcium channel blockers 爱杜西亚药品有限公司 2020-01-03 — — CN disclosed
WO-2009048527-A1 SUBSTITUTED BIPHENYL GPR40 MODULATORS AMGEN INC. (US) 2009-04-16 — — WO disclosed
US-20080255153-A1 New compounds BIOVITRUM AB (PUBL) (SE) 2008-10-16 — — US disclosed
WO-2008116898-A1 PYRAZOLO [1,5-A]PYRIMIDINES AS INHIBITORS OF STEAROYL-COA DESATURASE BIOVITRUM AB (PUBL) (SE) 2008-10-02 — — WO disclosed
US-20080090840-A1 Heterocyclic GPR40 Modulators AMGEN INC. (US) 2008-04-17 — — US disclosed
US-20080090840-A1 Heterocyclic GPR40 Modulators AMGEN INC. (US) 2008-04-17 — — US disclosed
US-20080090840-A1 Heterocyclic GPR40 Modulators AMGEN INC. (US) 2008-04-17 — — US disclosed
WO-2008030520-A1 HETEROCYCLIC GPR40 MODULATORS AMGEN INC. (US) 2008-03-13 — — WO disclosed
WO-2008030520-A1 HETEROCYCLIC GPR40 MODULATORS AMGEN INC. (US) 2008-03-13 — — WO disclosed
US-6271385-B1 FUNGICIDES (SUCH AS THOSE FOR USE IN FARMING AND HORTICULTURE). KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 2001-08-07 — — US disclosed
EP-1020441-A1 N-HETEROCYCLIC METHYLPROPYLAMINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND GERMICIDES KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 2000-07-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200223882-A1 Ectonucleotidase Inhibitors and Methods of Use Thereof NT5E, ENTPD5, NT5C2 EPHX1 93/4885KDM4A 2378/4885KDM5A 1679/4885
US-11034715-B2 Ectonucleotidase inhibitors and methods of use thereof NT5E, ENTPD5, NT5C2 EPHX1 93/4885KDM4A 2378/4885KDM5A 1679/4885
US-10570167-B2 Ectonucleotidase inhibitors and methods of use thereof NT5E, ENTPD5, NT5C2 EPHX1 93/4885KDM4A 2378/4885KDM5A 1679/4885
US-20080090840-A1 Heterocyclic GPR40 Modulators GPR119, GPR55, GPR65 EPHX1 2445/4885KDM4A 3657/4885KDM5A 3912/4885
US-20080255153-A1 New compounds SCD, SCD5, FADS2 EPHX1 1600/4885KDM4A 2198/4885KDM5A 1041/4885
US-20230002437-A1 ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF NT5E, ENTPD5, NT5C2 EPHX1 93/4885KDM4A 2378/4885KDM5A 1679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.